{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "shortName": "GH RESEARCH PLC  DL-,025", "messageBoardId": "finmb_707594028", "exchangeTimezoneShortName": "CEST", "market": "dr_market", "gmtOffSetMilliseconds": 7200000, "esgPopulated": false, "exchange": "FRA", "longName": "GH Research PLC", "regularMarketChangePercent": 4.878056, "regularMarketPrice": 8.6, "exchangeTimezoneName": "Europe/Berlin", "marketState": "REGULAR", "regularMarketChange": 0.40000057, "regularMarketTime": 1683892036, "regularMarketDayHigh": 8.6, "regularMarketDayRange": "8.55 - 8.6", "regularMarketDayLow": 8.55, "regularMarketVolume": 10, "regularMarketPreviousClose": 8.2, "bid": 9.6, "ask": 10.0, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 8.55, "averageDailyVolume3Month": 1, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 3.8400002, "fiftyTwoWeekLowChangePercent": 0.8067227, "fiftyTwoWeekRange": "4.76 - 15.8", "fiftyTwoWeekHighChange": -7.2, "fiftyTwoWeekHighChangePercent": -0.4556962, "fiftyTwoWeekLow": 4.76, "fiftyTwoWeekHigh": 15.8, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.36, "epsForward": -0.81, "epsCurrentYear": -0.43, "priceEpsCurrentYear": -20.0, "sharesOutstanding": 52020800, "bookValue": 4.802, "fiftyDayAverage": 7.334, "fiftyDayAverageChange": 1.2660003, "fiftyDayAverageChangePercent": 0.1726207, "twoHundredDayAverage": 9.667, "twoHundredDayAverageChange": -1.0669994, "twoHundredDayAverageChangePercent": -0.11037545, "marketCap": 493060384, "forwardPE": -10.617285, "priceToBook": 1.7909205, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.5 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1627279200000, "priceHint": 2, "symbol": "1KA.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Joshua Dawson House", "address2": "Dawson Street", "city": "Dublin", "zip": "D02 RY95", "country": "Ireland", "phone": "353 1 437 8334", "website": "https://www.ghres.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an intravenous mebufotenin product candidate; and GH003, an intranasal mebufotenin product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Mr. Florian  Schonharting M.Sc. (Econ)", "age": 53, "title": "Co-Founder & Non-Exec. Chairman", "yearBorn": 1969, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Theis  Terwey M.D.", "age": 46, "title": "Co-Founder & CEO", "yearBorn": 1976, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Magnus  Halle", "age": 25, "title": "Co-Founder & MD of Ireland", "yearBorn": 1997, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Julie  Ryan F.C.A.", "age": 36, "title": "VP of Fin.", "yearBorn": 1986, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Aaron  Cameron", "age": 37, "title": "VP of Technical Devel. & Operational Planning", "yearBorn": 1985, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}